Skip to main content
Signal8
Launch Terminal

ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

ImmunityBio, Inc. logo

ImmunityBio, Inc.

NASDAQ:IBRXHealthcare
-5.15%$8.29
AH$8.29+0.00%vs close
Mkt Cap$8.79B
Float395M
O/S1.06B
Vol
$ Vol
RVOL
Inst Own19.1%
Earnings
Dilution
ImmunityBio, Inc. logoNASDAQ:IBRX$8.29-5.15%
Upcoming Catalysts
Phase Distribution
83 lead-sponsored trials·16 active·18 completed
Phase 121
Phase 1/226
Phase 225
Phase 2/32
Phase 36
Not applicable3
(9 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

    Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)

    Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

    Enrollment
    433
    Start
    Jan 2014
    Primary Completion
    May 2017
    Completion
    May 2017
    NCT02049905
  • Phase 3
    Terminated

    Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

    NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab

    Non Small Cell Lung Cancer

    Enrollment
    102
    Start
    May 2018
    Primary Completion
    Oct 2025
    Completion
    Oct 2025
    NCT03520686
  • Phase 3
    Recruiting

    Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

    N-803, Tislelizumab

    NSCLC Stage IV

    Enrollment
    507
    Start
    Oct 2025
    Primary Completion
    Sep 2028est.
    Completion
    Jan 2029est.
    NCT06745908
  • Phase 3
    Withdrawn

    Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

    Nogapendekin alfa inbakicept (NAI), agenT-797

    Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS) +3

    Enrollment
    0
    Start
    Apr 2026est.
    Primary Completion
    Apr 2029est.
    Completion
    Dec 2029est.
    NCT07492875
  • Phase 3
    Withdrawn

    Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

    Drug: Nogapendekin alfa inbakicept (NAI), Pembrolizumab

    NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC

    Enrollment
    0
    Start
    May 2026est.
    Primary Completion
    May 2029est.
    Completion
    Dec 2029est.
    NCT07524257
  • Phase 3
    Withdrawn

    ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

    BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg)

    NMIBC

    Enrollment
    0
    Start
    May 2026est.
    Primary Completion
    May 2032est.
    Completion
    May 2032est.
    NCT07551544
  • Phase 2/3
    Active, not recruiting

    QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

    N-803 and BCG, N-803

    Bladder Cancer

    Enrollment
    190
    Start
    Jun 2017
    Primary Completion
    Oct 2024
    Completion
    Mar 2029est.
    NCT03022825
  • Phase 2/3
    Terminated

    A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

    hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)

    COVID-19

    Enrollment
    35
    Start
    Dec 2020
    Primary Completion
    Jun 2022
    Completion
    Jul 2023
    NCT06022224
  • Phase 2
    Completed

    Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

    INNO-206, Doxorubicin

    Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma +1

    Enrollment
    126
    Start
    Jan 2012
    Primary Completion
    Apr 2014
    Completion
    Dec 2014
    NCT01514188
  • Phase 2
    Completed

    Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

    INNO-206

    Pancreatic Ductal Adenocarcinoma

    Enrollment
    15
    Start
    May 2012
    Primary Completion
    May 2013
    Completion
    Jul 2013
    NCT01580397
  • Phase 2
    Completed

    Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

    250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin

    Glioblastoma

    Enrollment
    28
    Start
    Mar 2014
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02014844
  • Phase 2
    Completed

    A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

    50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin

    Kaposi's Sarcoma, HIV Positive +1

    Enrollment
    15
    Start
    Apr 2014
    Primary Completion
    Apr 2016
    Completion
    Apr 2016
    NCT02029430
  • Phase 2
    Completed

    Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

    Aldoxorubicin, Topotecan

    Metastatic Small Cell Lung Cancer

    Enrollment
    135
    Start
    Apr 2015
    Primary Completion
    May 2017
    Completion
    May 2017
    NCT02200757
  • Phase 2
    Terminated

    QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

    aNK (NK-92), aNK (NK-92) + N-803

    Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma

    Enrollment
    7
    Start
    Sep 2015
    Primary Completion
    Mar 2018
    Completion
    Mar 2018
    NCT02465957
  • Phase 2
    Active, not recruiting

    QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

    N-803 + Pembrolizumab, N-803 + Nivolumab

    Non-Small Cell Lung Cancer, Small Cell Lung Cancer +11

    Enrollment
    40
    Start
    Dec 2018
    Primary Completion
    Aug 2029est.
    Completion
    Dec 2030est.
    NCT03228667
  • Phase 2
    Withdrawn

    QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

    Leucovorin, 5-Fluorouracil

    Triple Negative Breast Cancer (TNBC)

    Enrollment
    0
    Start
    Sep 2018est.
    Primary Completion
    Jun 2020est.
    Completion
    Feb 2022
    NCT03554109
  • Phase 2
    Withdrawn

    QUILT-3.088: NANT Pancreatic Cancer Vaccine

    Gemcitabine, Nab-paclitaxel

    Metastatic Pancreatic Cancer

    Enrollment
    0
    Start
    Aug 2018est.
    Primary Completion
    Dec 2019est.
    Completion
    Feb 2022
    NCT03563144
  • Phase 2
    Withdrawn

    QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

    Nab-paclitaxel, Cisplatin

    Non Small Cell Lung Cancer

    Enrollment
    0
    Start
    Jun 2018est.
    Primary Completion
    Aug 2018est.
    Completion
    Aug 2018
    NCT03574649
  • Phase 2
    Terminated

    QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

    Avelumab, N-803

    Merkel Cell Carcinoma

    Enrollment
    9
    Start
    Feb 2020
    Primary Completion
    Sep 2021
    Completion
    Sep 2022
    NCT03853317
  • Phase 2
    Active, not recruiting

    Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

    N-803, Aldoxorubicin HCl

    Pancreatic Cancer

    Enrollment
    328
    Start
    Jul 2020
    Primary Completion
    Oct 2025
    Completion
    May 2026est.
    NCT04390399
  • Phase 2
    Active, not recruiting

    N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

    Bevacizumab, PD-L1 t-haNK

    Glioblastoma

    Enrollment
    34
    Start
    Aug 2024
    Primary Completion
    Dec 2029est.
    Completion
    Dec 2030est.
    NCT06061809
  • Phase 2
    Recruiting

    A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

    Gemcitabine, N-803

    Platinum-resistant Ovarian Cancer

    Enrollment
    20
    Start
    Nov 2024
    Primary Completion
    May 2027est.
    Completion
    May 2027est.
    NCT06710288
  • Phase 2
    Withdrawn

    Immunotherapy Before and After Surgery

    N-803, ETBX-071

    High-risk Prostate Cancer

    Enrollment
    0
    Start
    Dec 2025est.
    Primary Completion
    Jan 2031est.
    Completion
    Jun 2031est.
    NCT06765902
  • Phase 2
    Withdrawn

    Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

    N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus)

    High-risk Prostate Cancer

    Enrollment
    0
    Start
    Dec 2025est.
    Primary Completion
    Jan 2031est.
    Completion
    Jun 2031est.
    NCT06765954
  • Phase 2
    Not yet recruiting

    Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

    N-803 and BCG, N-803 and Gemcitabine

    Non-muscle Invasive Bladder Cancer (NMIBC)

    Enrollment
    20
    Start
    Nov 2025est.
    Primary Completion
    Nov 2026est.
    Completion
    Nov 2029est.
    NCT06829823

1-25 of 83

Search ClinicalTrials.gov for “ImmunityBio”